These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18279731)

  • 1. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.
    Ndrepepa G; Berger PB; Mehilli J; Seyfarth M; Neumann FJ; Schömig A; Kastrati A
    J Am Coll Cardiol; 2008 Feb; 51(7):690-7. PubMed ID: 18279731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials.
    Iijima R; Byrne RA; Ndrepepa G; Braun S; Mehilli J; Berger PB; Schömig A; Kastrati A
    Heart; 2009 Feb; 95(2):107-12. PubMed ID: 18801777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
    Kandzari DE; Berger PB; Kastrati A; Steinhubl SR; Mehilli J; Dotzer F; Ten Berg JM; Neumann FJ; Bollwein H; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2004 Dec; 44(11):2133-6. PubMed ID: 15582309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
    Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
    Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines.
    Winchester DE; Wen X; Brearley WD; Park KE; Anderson RD; Bavry AA
    J Am Coll Cardiol; 2011 Mar; 57(10):1190-9. PubMed ID: 21371635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
    Shishehbor MH; Topol EJ; Mukherjee D; Hu T; Cohen DJ; Stone GW; McClure R; Roffi M; Moliterno DJ;
    Am J Cardiol; 2006 Jun; 97(11):1585-90. PubMed ID: 16728219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT.
    Cho L; Bhatt DL; Wolski K; Lincoff M; Topol EJ; Moliterno DJ
    Am Heart J; 2001 Apr; 141(4):599-602. PubMed ID: 11275926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry.
    Lindsey JB; Marso SP; Pencina M; Stolker JM; Kennedy KF; Rihal C; Barsness G; Piana RN; Goldberg SL; Cutlip DE; Kleiman NS; Cohen DJ;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1074-82. PubMed ID: 19926047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
    Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A
    Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
    Barthélémy O; Silvain J; Brieger D; Mercadier A; Lancar R; Bellemain-Appaix A; Beygui F; Collet JP; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2012 Jan; 79(1):104-12. PubMed ID: 22162411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
    Nikolsky E; Aymong ED; Halkin A; Grines CL; Cox DA; Garcia E; Mehran R; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Cohen DA; Negoita M; Lansky AJ; Stone GW
    J Am Coll Cardiol; 2004 Aug; 44(3):547-53. PubMed ID: 15358018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
    Tornvall P; Nilsson T; Lagerqvist B
    J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
    Verheugt FW; Steinhubl SR; Hamon M; Darius H; Steg PG; Valgimigli M; Marso SP; Rao SV; Gershlick AH; Lincoff AM; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2011 Feb; 4(2):191-7. PubMed ID: 21349458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.